Reply from the authors [5]

Neurology

Volumn 68, Issue 10, 2007, Pages 797-

  Marshall, Frederick J ^a   Fahn, Stanley ^a   Clarence Smith, Kathleen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DIHYDROTETRABENAZINE; APOMORPHINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG METABOLITE; HALOPERIDOL; TETRABENAZINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

EID: 34247607666     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000259143.52138.5c     Document Type: Letter

References (8)

1. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
2. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-262.
3. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-521.
4. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate and placebo in patients with chorea. Lancet 1974;1:104-106.
5. Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202.
6. Scherman D, Jaudon P, Henry JP. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad Sci USA 1983;80:584-588.
7. Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987;76:461-465.
8. Kilbourn MR, Sherman PS, Kuszpit K. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies. Synapse 2002;43:188-194.